应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01177 中国生物制药
休市中 10-02 16:08:09
5.580
-0.130
-2.28%
最高
5.630
最低
5.440
成交量
3,527万
今开
5.605
昨收
5.710
日振幅
3.33%
总市值
1,043亿
流通市值
1,043亿
总股本
186.83亿
成交额
1.96亿
换手率
0.19%
流通股本
186.83亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
中国生物制药发布9月股份变动月报表，股本维持不变
公告速递 · 10-02 10:16
中国生物制药发布9月股份变动月报表，股本维持不变
异动解读｜中国生物制药盘中下跌4.29%，报5.465港元
行情直击 · 10-02 09:42
异动解读｜中国生物制药盘中下跌4.29%，报5.465港元
中国生物制药盘中涨超4% 花旗维持“买入”评级
新浪港股 · 09-30 11:30
中国生物制药盘中涨超4% 花旗维持“买入”评级
异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化
行情直击 · 09-30 10:27
异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化
花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级
智通财经 · 09-29
花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级
中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城
北京商报 · 09-29
中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城
异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作
行情直击 · 09-29
异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作
中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元
财中社 · 09-28
中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元
中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款
公告速递 · 09-28
中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款
中国生物制药(01177.HK)附属与STADA就生物类似药达成战略合作
智通财经 · 09-28
中国生物制药(01177.HK)附属与STADA就生物类似药达成战略合作
中国生物制药2026年中期财报：营收194.4亿元，经调整净利润33.4亿元
公告速递 · 09-24
中国生物制药2026年中期财报：营收194.4亿元，经调整净利润33.4亿元
【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估
金吾财讯 · 09-24
【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估
美银证券：中国医疗保健行业加快创新及全球化 上调中生制药(01177.HK)目标价至7.3港元
智通财经 · 09-21
美银证券：中国医疗保健行业加快创新及全球化 上调中生制药(01177.HK)目标价至7.3港元
港股早盘震荡分化 恒指半日涨0.56% 中国生物制药（01177）升8.68%
金吾财讯 · 09-21
港股早盘震荡分化 恒指半日涨0.56% 中国生物制药（01177）升8.68%
港股异动 | 中国生物制药(01177)涨超6% 公司重申年内收入指引 新获批创新药将是销售持续放量主要动力
智通财经 · 09-21
港股异动 | 中国生物制药(01177)涨超6% 公司重申年内收入指引 新获批创新药将是销售持续放量主要动力
异动解读｜中国生物制药盘中上涨3.11%，大和重申买入评级叠加创新药管线密集催化
行情直击 · 09-21
异动解读｜中国生物制药盘中上涨3.11%，大和重申买入评级叠加创新药管线密集催化
大和：引述中国生物制药管理层重申今年收入增长双位数指引 给予“买入”评级
新浪港股 · 09-20
大和：引述中国生物制药管理层重申今年收入增长双位数指引 给予“买入”评级
大和：引述中国生物制药(01177.HK)管理层重申今年收入增长双位数指引 评级“买入”
智通财经 · 09-18
大和：引述中国生物制药(01177.HK)管理层重申今年收入增长双位数指引 评级“买入”
大和：引述中国生物制药(01177)管理层重申今年收入增长双位数指引 评级“买入”
智通财经 · 09-18
大和：引述中国生物制药(01177)管理层重申今年收入增长双位数指引 评级“买入”
异动解读｜中国生物制药盘中上涨3.18%，双品种新药上市申请获受理叠加增持正大天晴股权落地
行情直击 · 09-18
异动解读｜中国生物制药盘中上涨3.18%，双品种新药上市申请获受理叠加增持正大天晴股权落地
加载更多
公司概况
公司名称：
中国生物制药
所属市场：
SEHK
上市日期：
--
主营业务：
中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。
发行价格：
--
{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.58,"timestamp":1790928489003,"preClose":5.71,"halted":0,"volume":35272501,"delay":0,"changeRate":-0.022767075306479843,"floatShares":18683000000,"shares":18683000000,"eps":0.15188102559052027,"marketStatus":"休市中","change":-0.13,"latestTime":"10-02 16:08:09","open":5.605,"high":5.63,"low":5.44,"amount":195822331,"amplitude":0.033275,"askPrice":5.585,"askSize":1570000,"bidPrice":5.58,"bidSize":106000,"shortable":3,"etf":0,"ttmEps":0.15534459492270264,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.71,"dividendRate":0.021487,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.5787411179262746,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.0905,"impliedVolPercentile":0.0245},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1118259959","title":"中国生物制药发布9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118259959","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118259959?lang=zh_cn&edition=full","pubTime":"2026-10-02 10:16","pubTimestamp":1790907413,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年10月2日公布截至2026年9月30日的证券变动月报表。公告显示，公司本月法定/注册股本维持在300亿股，面值每股0.025港元，总额7.50亿港元。已发行股份合计仍为186.82952230亿股，本月无新增发股本，也无库藏股变动。根据公告显示，中国生物制药在2026年1月13日曾签订收购合同，计划向Dracoo Investment Limited以每股6.66港元发行约1459.6322万股普通股作为部分对价，但上述股份将在未来年度分期配发，目前本月并未实际发行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152057483","title":"异动解读｜中国生物制药盘中下跌4.29%，报5.465港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152057483","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152057483?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:42","pubTimestamp":1790905320,"startTime":"0","endTime":"0","summary":"10月2日，中国生物制药盘中下跌4.29%，报5.465港元，成交额3331.3万港元。中国生物制药所在的制药行业整体承压，个股中，翰森制药跌4.25%，石药集团跌3.77%，恒瑞医药跌3.59%，凯莱英跌5.99%，神威药业跌3.0%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222653","title":"中国生物制药盘中涨超4% 花旗维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222653","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222653?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:30","pubTimestamp":1790739000,"startTime":"0","endTime":"0","summary":"模拟交易客户端中国生物制药盘中涨超4%，截至发稿，股价上涨2.79%，现报5.705港元，成交额2.15亿港元。该行认为合作带来惊喜，并维持中生制药“买入”评级，目标价10.8港元。根据协议，正大天晴将收取首付款及高达5，300万欧元的开发、监管及销售里程碑付款，并享有双位数利润分成；正大天晴仍负责开发、生产及商业供应，合作亦包括最多另外三个肿瘤及免疫领域生物类似药分子的选择权。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-30/doc-initqqvm2508465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107465291","title":"异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1107465291","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107465291?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:27","pubTimestamp":1790735233,"startTime":"0","endTime":"0","summary":"9月30日，中国生物制药盘中上涨3.33%，报5.74港元，成交额9824.52万港元。消息面上，公司近日公告，附属公司正大天晴与德国药企STADA就帕博利珠单抗生物类似药TQB3570达成独家战略合作，授予STADA在欧盟、瑞士、英国及独联体的商业化权利，双方还可选择将最多三款肿瘤及免疫领域生物类似药纳入合作。公司透露年内对外授权交易累计首付款及近期里程碑付款已达3.55亿美元，潜在总交易金额达34亿美元，国际化布局持续加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药上涨，STADA合作持续催化","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671800297","title":"花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671800297","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671800297?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:42","pubTimestamp":1790671365,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，中国生物制药旗下正大天晴与德国药企STADA就生物类似药达成战略合作，授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药的独家许可，并可选择拓展至美国及海湾合作委员会成员国市场。中生制药透露年内对外授权交易合计首付款及近期里程碑付款达3.55亿美元，潜在总交易金额达34亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","PPH","XPH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671529451","title":"中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城","url":"https://stock-news.laohu8.com/highlight/detail?id=2671529451","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671529451?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:50","pubTimestamp":1790668212,"startTime":"0","endTime":"0","summary":"产品还未进入临床便火速敲定了合作。9月28日晚间，中国生物制药发布公告称，公司附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，授予后者在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药TQB3570的独家许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886461514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886461514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","01177","BK1589","SBHMY","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181435389","title":"异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1181435389","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181435389?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:47","pubTimestamp":1790646437,"startTime":"0","endTime":"0","summary":"9月29日，中国生物制药盘中上涨3.18%，报5.67港元，成交额5400.88万港元。消息面上，公司9月28日公告，附属公司正大天晴药业集团与德国STADA就帕博利珠单抗生物类似药TQB3570达成独家战略合作。STADA获得欧盟、瑞士、英国等地区的独家商业化权利，双方还可选择将最多三款肿瘤及免疫领域生物类似药纳入合作。公司年内已累计获得首付款及近期里程碑付款3.55亿美元，潜在总交易金额达34亿美元，国际化布局持续加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药放量上涨，与STADA达成战略合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670387092","title":"中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670387092","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670387092?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:57","pubTimestamp":1790585820,"startTime":"0","endTime":"0","summary":"9月28日，中国生物制药（01177）发布公告，附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，双方将携手提升生物类似药在全球多个地区的患者可及性。根据协议的条款及条件，正大天晴将获得首付款，并有权获得潜在开发、监管及销售里程碑付款，合计最高可达5300万欧元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885246557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885246557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","LU1992135472.HKD","IE00BZ08YR35.GBP","FXE","LU2272731865.HKD","LU2272731600.USD","LU2272731782.SGD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK4585","BK1589","LU2322448957.HKD","LU2473716301.USD","LU1992135399.USD","IE00B5TLWC47.USD","NBIE","PPH","IE00BZ08YT58.USD","BK4588","XPH","BK1191","LU2322448791.USD","BK1521","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195589634","title":"中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=1195589634","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195589634?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:53","pubTimestamp":1790585586,"startTime":"0","endTime":"0","summary":"2026年9月28日，中国生物制药公告称，其附属公司正大天晴药业集团股份有限公司与 STADA Arzneimittel AG 就帕博利珠单抗生物类似药达成战略合作，双方将共同提升该类产品在全球多地区的可及性。双方还约定，STADA可再选择最多三款覆盖肿瘤及免疫领域的生物类似药分子。公告显示，2026年以来，中国生物制药已完成多项对外授权交易，累计获得首付款及近期里程碑付款3.55亿美元，潜在总交易金额34亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670850238","title":"中国生物制药(01177.HK)附属与STADA就生物类似药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2670850238","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670850238?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:49","pubTimestamp":1790585397,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01177","BK1521","BK1191","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","HK0000165453.HKD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151633180","title":"中国生物制药2026年中期财报：营收194.4亿元，经调整净利润33.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151633180","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151633180?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:08","pubTimestamp":1790240884,"startTime":"0","endTime":"0","summary":"中国生物制药发布2026年中期业绩。期内，公司实现收入194.4亿元，同比增长10.6%。经调整净利润为33.4亿元，同比增长8.1%。毛利率约为83.0%，经营活动产生的现金流净额约43.19亿元，同比增长36.6%。财报显示，上半年销售及分销成本约52.60亿元，同比下降18.4%；行政费用约9.69亿元，同比下降11.4%。公司研究与开发投入约32.91亿元，约占总收入的16.9%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药2026年中期财报：营收194.4亿元，经调整净利润33.4亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU2097828805.USD","01801","IBBQ","LU1152091168.USD","01177","LU0314109678.HKD","LU0348784397.USD","HK0000165453.HKD","LU0315179316.USD","BK1515","LU0516423091.SGD","600109","02616","01877","LU1226287792.SGD","02142","LU1226288253.USD","09926","LU0708995583.HKD","LU1251922891.USD","LU1152091754.HKD","01093","09995","KCE","LU0828237510.HKD","06160","KURE","LU2476274720.SGD","LU1993786604.SGD","LU3063872942.SGD","MEDX","IE00B5MMRT66.SGD","159992","06978","SG9999002562.SGD","LU1770034418.SGD","06185","LU0348766576.USD","LU1719994722.HKD","LU0128526141.USD","LNGR","LU0039217434.USD","LU0417516902.SGD","LU0359202008.SGD","LU0029874061.USD","LU2039709279.SGD","LU0320764599.SGD","09688","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155057","title":"美银证券：中国医疗保健行业加快创新及全球化 上调中生制药(01177.HK)目标价至7.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155057","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669155057?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:45","pubTimestamp":1789976746,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YT58.USD","01477","BK1589","BK1574","BK1521","BK1515","BK1191","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669020134","title":"港股早盘震荡分化 恒指半日涨0.56% 中国生物制药（01177）升8.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669020134","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669020134?lang=zh_cn&edition=full","pubTime":"2026-09-21 12:12","pubTimestamp":1789963977,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股指数早盘震荡分化，医药板块强势，科技板块承压，截至午间收盘，恒生指数上涨0.56%；国企指数涨0.70%；恒生科技指数下跌0.13%。家电股走低，海尔智家跌4.03%，创维集团跌3.66%，美的集团跌2.97%，TCL电子跌2.61%，海信家电跌2.18%。国金证券表示，8月家电社零由负转正。个股方面，阿里健康股价持续受压，午间收跌4.73%。英派药业-B逆市拉升，午间收涨42.13%。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"other","thumbnail":"https://static.szfiu.com/news/20200915/ZTMxNjQ3ZDUxMTYwMDE1MDQzMDE2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/ZTMxNjQ3ZDUxMTYwMDE1MDQzMDE2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03115","07200","SBHMY","01177","BK1521","513600","03419","82800","HK0000165453.HKD","IE00BZ08YT58.USD","HSTECH","IE00BZ08YS42.EUR","07500","83115","HSI","BK1515","09115","BK1589","07300","03037","BK1191","HHImain","MCHmain","IE00BZ08YR35.GBP","02800","02833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669513932","title":"港股异动 | 中国生物制药(01177)涨超6% 公司重申年内收入指引 新获批创新药将是销售持续放量主要动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2669513932","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669513932?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:06","pubTimestamp":1789956376,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超6%，截至发稿，涨6.58%，报5.83港元，成交额1.92亿港元。消息面上，大和发布研报称，在近日举行医疗健康行业交流活动上，中国生物制药管理层重申今年收入录得双位数同比增幅的指引未变，预期可由授权收入及创新药销售增长共同带动，并预期创新药销售加上授权收入将贡献全年收入一半。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","LNGR","BK4588","IE00BZ08YS42.EUR","06978","BK1574","VXUS","BK4585","HK0000165453.HKD","BK1161","MEDX","IBBQ","BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","159992","BK1589","KCAI","BK1521","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169107497","title":"异动解读｜中国生物制药盘中上涨3.11%，大和重申买入评级叠加创新药管线密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1169107497","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169107497?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:38","pubTimestamp":1789954702,"startTime":"0","endTime":"0","summary":"9月21日，中国生物制药盘中上涨3.11%，报5.66港元/股，成交额4044.66万港元。消息面上，大和近日发布研报，引述公司管理层重申今年收入录得双位数同比增幅的指引未变，预期由授权收入及创新药销售增长共同带动，创新药销售加上授权收入将贡献全年收入一半，给予\"买入\"评级。高盛此前亦将目标价上调至9.07港元，重申\"买入\"评级，上调盈利预测主要反映少数股东权益下降及商务拓展贡献概率提高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药盘中上涨，创新药管线密集催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668189776","title":"大和：引述中国生物制药管理层重申今年收入增长双位数指引 给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2668189776","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668189776?lang=zh_cn&edition=full","pubTime":"2026-09-20 20:16","pubTimestamp":1789906560,"startTime":"0","endTime":"0","summary":"模拟交易客户端大和发布研报称，日前举行医疗健康行业交流活动，中国生物制药管理层重申今年收入录得双位数同比增幅的指引未变，预期可由授权收入及创新药销售增长共同带动，并预期创新药销售加上授权收入将贡献全年收入一半。大和目前对中生制药评级为“买入”。管理层亦透露，新获批创新药将是销售持续放量的主要动力，另预期仿制药业务将于今年见底后，在较低基数下明年或重拾增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-20/doc-inisnssu9243619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668910223","title":"大和：引述中国生物制药(01177.HK)管理层重申今年收入增长双位数指引 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2668910223","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668910223?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:02","pubTimestamp":1789711362,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01177","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1515","BK1589","HK0000165453.HKD","BK1521","BK1191","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668221910","title":"大和：引述中国生物制药(01177)管理层重申今年收入增长双位数指引 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2668221910","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668221910?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:02","pubTimestamp":1789711362,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，日前举行医疗健康行业交流活动，中国生物制药管理层重申今年收入录得双位数同比增幅的指引未变，预期可由授权收入及创新药销售增长共同带动，并预期创新药销售加上授权收入将贡献全年收入一半。大和目前对中生制药评级为“买入”。管理层亦透露，新获批创新药将是销售持续放量的主要动力，另预期仿制药业务将于今年见底后，在较低基数下明年或重拾增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大和：引述中国生物制药(01177)管理层重申今年收入增长双位数指引 评级“买入”","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134746194","title":"异动解读｜中国生物制药盘中上涨3.18%，双品种新药上市申请获受理叠加增持正大天晴股权落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1134746194","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134746194?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:59","pubTimestamp":1789696759,"startTime":"0","endTime":"0","summary":"9月18日，中国生物制药盘中上涨3.18%，报5.67港元/股，成交额5693.27万港元。消息面上，公司近日密集释放利好：9月16日，核心子公司正大天晴自主研发的两款国家1类创新药——TQH2722注射液及TQB2102注射液的新药上市申请均获CDE受理。同日，公司以44.8亿元收购正大天晴5%股权完成交割，持股由60%升至65%，对应约19倍LTM市盈率，预计增厚经调整归母净利润约3.5亿元。高盛此前已上调目标价至9.07港元，重申\"买入\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药放量上涨，双创新药上市申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":0.0608},{"period":"3month","weight":0.1926},{"period":"6month","weight":-0.0968},{"period":"1year","weight":-0.3153},{"period":"ytd","weight":-0.0749}],"compareEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":-0.0529},{"period":"3month","weight":0.0266},{"period":"6month","weight":-0.0456},{"period":"1year","weight":-0.1215},{"period":"ytd","weight":-0.0647}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.006945},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056473},{"month":3,"riseRate":0.565217,"avgChangeRate":0.04606},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020913},{"month":5,"riseRate":0.695652,"avgChangeRate":0.038341},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004417},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052281},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.006702},{"month":9,"riseRate":0.434783,"avgChangeRate":-0.011268},{"month":10,"riseRate":0.521739,"avgChangeRate":0.022581},{"month":11,"riseRate":0.5,"avgChangeRate":0.067433},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.011901}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}